MacroGenics Shares Pop on 2028 Cash Runway Focus
MacroGenics shares rose 4.1% to $4.22 Wednesday, outperforming biotech peers as investors revisited its cash position and clinical timeline. The company reported a Q1 net loss of $36.8 million on $20.8 million revenue, with $154.2 million in cash and marketable securities as of March 31, not including a recent $60 million payment. MacroGenics expects its funding to last into 2028. Broader U.S. markets traded lower.